1-amino-3-tert-butoxypropan-2-ol

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-amino-3-tert-butoxypropan-2-ol
• 英文别名: 1-amino-3-tert.-butoxy-2-propanol；1-amino-3-tert-butoxy-2-propanol；1-Amino-3-(tert-butoxy)propan-2-ol；1-amino-3-[(2-methylpropan-2-yl)oxy]propan-2-ol
• 化学式: C₇H₁₇NO₂
• 分子量: 147.217
• InChiKey: ZKHHFKLWZNETDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  55.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(4-氯苯甲酰)丙酸 、 1-amino-3-tert-butoxypropan-2-ol 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以39%的产率得到(2S,7aR)-7a-(4-chlorophenyl)-2-[(2-methylpropan-2-yl)oxymethyl]-2,3,6,7-tetrahydropyrrolo[2,1-b][1,3]oxazol-5-one
  参考文献：
  名称：

  Substituted Tetrahydropyrrolo[2,1-b]oxazol-5(6H)-ones and Tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones as Hypoglycemic Agents

  摘要：

  A series of substituted tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one and tetrahydropyrrolo[2,1-b]thiazol-5(6H)-ones was synthesized from amino alcohols or amino thiols and keto acids. A pharmacological model based on the results obtained with these compounds led to the synthesis and evaluation of a series of isoxazoles and other monocyclic compounds. These were evaluated for their ability to enhance glucose utilization in cultured L6 myocytes. The in vivo hypoglycemic efficacy and potency of these compounds were evaluated in a model of type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus), the ob/ob mouse. 25a(2S) (SDZ PGU 693) was selected for further pharmacological studies.

  DOI：

  10.1021/jm9803121
• 作为产物：
  描述：

  叔丁基缩水甘油醚 在 氨 作用下， 以 甲醇 为溶剂， 生成 1-amino-3-tert-butoxypropan-2-ol
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIDINES AND METHOD OF USE
  [FR] PYRIDINES SUBSTITUÉES ET MÉTHODE D'UTILISATION

  摘要：

  该发明公开了式（I）化合物，其中X、R1、R2和R3如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予该发明的化合物来治疗囊性纤维化的方法。

  公开号：

  WO2016193812A1

文献信息

• Naphthyloxazolidone derivatives
  申请人：Tanabe Seiyaky Co., Ltd.

  公开号：US05182296A1

  公开（公告）日：1993-01-26

  A naphthyloxazolidone derivative of the formula: ##STR1## wherein R.sup.1 is hydrogen atom, hydroxy group, nitro group, amino group, sulfo group, aminosulfoyul group, a lower alkenyloxy group, a lower alkynyloxy group, a mono or di(lower alkyl)aminocarbonyloxy group, a lower alkanoyloxy group or a lower alkoxy group which may have a substituent selected from an aryl group, a cycloalkyl group, an oxygen-containing heteromonocyclic group, hydroxy group, a lower alkoxy group, cyano group, a di(lower alkyl)amino group, aminocarbonyl group, a lower alkoxycarbonyl group, a lower alkanoyloxy group, a lower alkylthio group, a lower alkylsulfinyl group and a lower alkylsulfonyl group; R.sup.2 is hydroxy group, a lower alkoxy group, a lower alkylsulfonyloxy group, triazo group or an amino group which may have a substituent selected from a lower alkyl group and a lower alkanoyl group, and a pharmaceuticaly acceptable salt thereof are disclosed. Said derivative and a pharmaceutically acceptable salt thereof are useful as an antidepressant.

  公开了一种萘氧唑酮衍生物，其化学式为：##STR1##其中R.sup.1是氢原子，羟基，硝基，氨基，磺酰基，氨基磺酰基，较低的烯基氧基，较低的炔基氧基，单或双(较低的烷基)氨基羧酸酯氧基，较低的烷酰氧基或较低的烷氧基，其可以具有被选择自芳基，环烷基，含氧杂环单环基团，羟基，较低的烷氧基，氰基，二(较低的烷基)氨基基团，氨基羧基，较低的烷氧羰基基团，较低的烷酰氧基，较低的烷基硫基，较低的烷基亚砜基和较低的烷基磺酰基取代的基团。R.sup.2是羟基，较低的烷氧基，较低的烷基磺酰氧基，三唑基或氨基，其可以具有被选择自较低的烷基和较低的烷酰基取代的基团，以及其药学上可接受的盐。所述衍生物及其药学上可接受的盐在抗抑郁治疗中有用。
• GLYCOGEN-BASED WATER SOLUBILITY ENHANCERS
  申请人：Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.

  公开号：EP2981557B1

  公开（公告）日：2020-02-05
• SUBSTITUTED PYRIDINES AND METHOD OF USE
  申请人：Abbvie S.a.r.l.

  公开号：EP3303294A1

  公开（公告）日：2018-04-11
• SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200039961A1

  公开（公告）日：2020-02-06

  The present disclosure relates to substituted fused bi- or tri-heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering a substituted fused bi- or tri-heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
• COMBINATION THERAPIES WITH EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200054635A1

  公开（公告）日：2020-02-20

  The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.